Stock Track | Aurinia Pharmaceuticals Soars on Blowout Q3 Earnings Beat

Stock Track

Nov 07, 2024

Aurinia Pharmaceuticals Inc. (AUPH) reported third quarter 2024 adjusted earnings per share of $0.10, crushing the analyst consensus estimate of $0.01. The company's quarterly revenue of $67.8 million also handily beat Wall Street's expectations of $57.69 million.

The strong quarterly results marked a 24.37% year-over-year increase in sales compared to the same period last year. Aurinia's Q3 earnings per share exceeded estimates by a staggering 900%, while revenue surpassed projections by over 17%.

Earnings that significantly exceed market expectations tend to be viewed as a major positive for a company and can spark buying interest in the stock. Aurinia's blowout Q3 numbers appear to be the catalyst driving the pre-market surge of over 6.5% in the pharmaceutical firm's shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1185222767"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185222767\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185222767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185222767","market":"us","top_or_hot":-1,"title":"Stock Track | Aurinia Pharmaceuticals Soars on Blowout Q3 Earnings Beat","media":"Stock Track","content":"<p>Aurinia Pharmaceuticals Inc. (AUPH) reported third quarter 2024 adjusted earnings per share of $0.10, crushing the analyst consensus estimate of $0.01. The company's quarterly revenue of $67.8 million also handily beat Wall Street's expectations of $57.69 million.</p>\n\n<p>The strong quarterly results marked a 24.37% year-over-year increase in sales compared to the same period last year. Aurinia's Q3 earnings per share exceeded estimates by a staggering 900%, while revenue surpassed projections by over 17%.</p>\n\n<p>Earnings that significantly exceed market expectations tend to be viewed as a major positive for a company and can spark buying interest in the stock. Aurinia's blowout Q3 numbers appear to be the catalyst driving the pre-market surge of over 6.5% in the pharmaceutical firm's shares.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Aurinia Pharmaceuticals Soars on Blowout Q3 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Aurinia Pharmaceuticals Soars on Blowout Q3 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-07 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aurinia Pharmaceuticals Inc. (AUPH) reported third quarter 2024 adjusted earnings per share of $0.10, crushing the analyst consensus estimate of $0.01. The company's quarterly revenue of $67.8 million also handily beat Wall Street's expectations of $57.69 million.</p>\n\n<p>The strong quarterly results marked a 24.37% year-over-year increase in sales compared to the same period last year. Aurinia's Q3 earnings per share exceeded estimates by a staggering 900%, while revenue surpassed projections by over 17%.</p>\n\n<p>Earnings that significantly exceed market expectations tend to be viewed as a major positive for a company and can spark buying interest in the stock. Aurinia's blowout Q3 numbers appear to be the catalyst driving the pre-market surge of over 6.5% in the pharmaceutical firm's shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUPH","symbol_name":"Aurinia Pharmaceuticals Inc","start_time":0,"source_url":"","article_id":"1185222767","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185222767","pubTimestamp":1730977597,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Aurinia Pharmaceuticals Inc.  reported third quarter 2024 adjusted earnings per share of $0.10, crushing the analyst consensus estimate of $0.01. The company's quarterly revenue of $67.8 million also handily beat Wall Street's expectations of $57.69 million.The strong quarterly results marked a 24.37% year-over-year increase in sales compared to the same period last year. Aurinia's Q3 earnings per share exceeded estimates by a staggering 900%, while revenue surpassed projections by over 17%.Earn","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUPH":"Aurinia Pharmaceuticals Inc"},"translate_title":"股票轨迹Aurinia Pharmaceuticals因第三季度盈利井喷而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUPH":1},"content_text":"Aurinia Pharmaceuticals Inc. (AUPH) reported third quarter 2024 adjusted earnings per share of $0.10, crushing the analyst consensus estimate of $0.01. The company's quarterly revenue of $67.8 million also handily beat Wall Street's expectations of $57.69 million.\nThe strong quarterly results marked a 24.37% year-over-year increase in sales compared to the same period last year. Aurinia's Q3 earnings per share exceeded estimates by a staggering 900%, while revenue surpassed projections by over 17%.\nEarnings that significantly exceed market expectations tend to be viewed as a major positive for a company and can spark buying interest in the stock. Aurinia's blowout Q3 numbers appear to be the catalyst driving the pre-market surge of over 6.5% in the pharmaceutical firm's shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}